Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure

Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis

“…The reported 3-and 5 year OS of 78.6% and 71.4% are comparable to that reported in both randomized and other retrospective studies (5,6,17,18). The ACT I trial reported a 3-year OS of 65% in their CRT group consisting of 292 patients clinically staged as T2N0 or higher (17).…”

“…In the Accord 03, a 5-year OS of 71% -74.5% was reported in 307 patients with tumors > 4 cm and/or N+ disease treated with CRT (18). The Montpellier study found a 5-year OS of 74% in 193 patients treated with CRT, and Mitra et al reported a 4-year OS of 85.8% in 99 patients in all disease stages, treated with CRT (5,6). The relatively low OS in the ACT I may be attributed to the inclusion of only more advanced stages of disease as well as stage migration over the years (inclusion ended in 1994, MRI and PET CT scans were not widely available at that time).…”

Predicting outcomes in anal cancer patients using multi-centre data and distributed learning – A proof-of-concept study

“…Shakir et al [29] reported outcome data from 385 patients treated with IMRT in five UK centres, with median follow-up of 24 months. de Meric de Bellefon et al [30] recently published long-term outcomes, including late toxicity data, for 193 patients treated with IMRT in a single French centre. No other studies have reported on cohorts of this size, and none with multi-national data.…”

Circulating tumor-tissue modified HPV DNA analysis for molecular disease monitoring after chemoradiation for anal squamous cell carcinoma: a case report

“…This early response assessment could potentially inform patient candidacy regarding de-escalated treatment approaches. Such studies would be of great interest because patients treated with chemoRT consisting of 5-FU, mitomycin C, and 50.4-54 Gy for anal cancer accept significant risks of toxicity, including a ~40% rate of hospitalization within 3 months after chemoRT (8), as well as late side effects which can adversely affect sexual health, gastrointestinal function, and bone strength (9,10). Meanwhile, local control may approach 100% in selected contemporary series treating HPV-positive disease with standard doses (11), and doses as low as 30 Gy as per the Nigro experience may be adequate for at least some patients (12).…”